Project Grant R01CA301569
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $708K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $176,040 Project Grant to Massachusetts General Hospital under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. The award funds research to develop engineered CAR-T (Chimeric Antigen Receptor T) cell therapies capable of overcoming the cancer cell glycocalyx barrier, a protective layer that impedes immune cell recognition and destruction of solid tumors. The research addresses a...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $195,240 Project Grant on September 17, 2025, under the Cancer Research Manpower program (CFDA 93.398) to Massachusetts General Hospital to develop innovative research methodologies for correlating genotype and phenotype in metastatic cancer cells. The project, spanning through August 31, 2030, will deliver a single-cell assay platform utilizing laser particles (LPs)—biocompatible optical barcoding particles that emit...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $628,373 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025, for a five-year project period extending through June 30, 2030. This Project Grant supports fundamental and translational research focused on understanding the immunobiology of conventional dendritic cells (CDC1) and their...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $817,829 Project Grant on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention designed to improve quality of life in lymphoma survivors during early post-treatment survivorship (0-2 years post-active treatment). The study will enroll 254...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $673,096 Project Grant on August 18, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to improve cancer and mental health care delivery for adults with serious mental illness (SMI). The award supports a multi-site cancer center network trial through July 31, 2030, implementing the BRIDGE Model—a person-centered collaborative care intervention that integrates proactive...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 19, 2025, with a completion date of August 31, 2029. The award funds development and clinical translation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform that leverages CRISPR-based biosensing to detect cancer biomarkers...